Metraipolis › archive › dc_6ab6db16fc31
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study — Europe PMC PMID:40685251
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40685251
- DOI
- 10.1093/ehjcvp/pvaf053
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T21:08:32.272Z
- SHA-256 of the archived text
b1ce89bd5b9e92ea07119ccf3d2b8a617026b0bcebd556ab10cbba2bd724109a- Stable URL of this page
https://metraipolis.com/documento/dc_6ab6db16fc31
How to cite
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study — Europe PMC PMID:40685251 — Europe PMC (en), https://europepmc.org/article/MED/40685251 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6ab6db16fc31 (Metraipolis archive dc_6ab6db16fc31, sha256 b1ce89bd5b9e92ea07119ccf3d2b8a617026b0bcebd556ab10cbba2bd724109a)
BibTeX
@misc{dc6ab6db16fc31,
title = {Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study — Europe PMC PMID:40685251},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40685251},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6ab6db16fc31; sha256 b1ce89bd5b9e92ea07119ccf3d2b8a617026b0bcebd556ab10cbba2bd724109a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40685251. Agents can read the archived copy with the MCP tool read_document.